Actively Recruiting
Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease
Led by Cell Biopeutics Resources Sdn Bhd · Updated on 2025-09-09
10
Participants Needed
1
Research Sites
204 weeks
Total Duration
On this page
Sponsors
C
Cell Biopeutics Resources Sdn Bhd
Lead Sponsor
S
Stempeutics Research Pvt Ltd
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational, practice-based feasibility study is to observe the efficacy and safety of intramuscular administration of Stempeucel® in Malaysian patients with critical limb ischemia (CLI) due to peripheral arterial disease. The main questions it aims to answer are: * Can intramuscular administration of Stempeucel® reduce symptoms of CLI due to peripheral arterial disease while improving the healing rate and functional outcomes? * Does intramuscular administration of Stempeucel® causes any serious adverse events in CLI due to peripheral arterial disease patients? Study patients will be assessed by the PI before administering the Stempeucel® for any other organ with inflammation. The study patients will also be followed up to the duration of 1 year after study treatment administration for safety and efficacy assessment.
CONDITIONS
Official Title
Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients between 18-65 years old
- Patients diagnosed with atherosclerotic peripheral arterial disease
- Patients not eligible for or have failed surgical or percutaneous revascularization
- Patients with at least one ulcer between 0.5 to 10 cm2 in size
- Ankle brachial pressure index (ABPI) 60.6 or toe brachial index (TBI) 60.5 if ABPI is out of range
- Patients able and willing to provide consent and comply with study procedures and follow-up
You will not qualify if you...
- Patients diagnosed with Buerger's disease by Shionoya criteria
- Patients eligible for surgical or percutaneous revascularization
- Patients who participated in another stem cell trial or therapy within 3 months
- Patients deemed unsuitable for the clinical trial by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital Canselor Tunku Mukhriz
Kuala Lumpur, Malaysia, 56000
Actively Recruiting
Research Team
J
Jezamine Lim, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here